跳至主要内容
临床试验/NCT06777511
NCT06777511尚未招募不适用

Advancing Antimicrobial Photodynamic Therapy to Prevent Infection in Osseointegrated Prosthesis Patients

Dartmouth-Hitchcock Medical Center1 个研究点 分布在 1 个国家目标入组 10 人开始时间: 2026年10月1日最近更新:
干预措施
相关药物

试验速览

阶段
不适用
状态
尚未招募
入组人数
10
试验地点
1
主要终点
Feasibility

研究概览

简要总结

This will be a prospective observational trial enrolling 20 patients with osseointegrated prostheses. Participants will be recruited from the orthopaedic outpatient clinic at Walter Reed National Military Medical Center in Bethesda, MD.

All eligible consenting patients will undergo daily stoma management per standard of care.

Patients will integrate antimicrobial photodynamic therapy into their stoma management program. The first treatment will take place in the orthopaedic clinic. All others will take place at home. Topical 5-ALA will be applied to the metal at the penetration site. After 2 hours, the light delivery device will be utilized and light will be administered for 15 minutes.

Data collection: After obtaining informed consent, study personnel will record injury-specific variables, surgery-specific variables, other variables related to their hospital course, demographic variables as well as comorbidities on the study case report forms (CRFs). They will obtain this information directly from the participant, from the participant's medical record, and the participant's treating orthopaedic surgeon or other health care providers. Baseline data collection points include participant characteristics and amputation details such as age, sex, comorbidities, highest education level achieved, social support, initial reason for amputation, type of amputation and all surgical dates. Study participants will be followed at 1 and 2 weeks after initiation of PDT treatment. To ensure research participant safety, serious adverse events (SAEs) will be documented and promptly submitted to the local IRB as per the required reporting processes.

Follow-up: Study participants will be followed at 1 week and 2 weeks.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • All patients with osseointegrated prostheses 18 years of age or older

排除标准

  • Ongoing infection
  • Anticipated issues with compliance or follow-up

研究组 & 干预措施

Osseointegration patients

All patients >18 years with osseointegrated prostheses.

干预措施: 5-aminolevulinic acid (5-ALA) (Drug)

Osseointegration patients

All patients >18 years with osseointegrated prostheses.

干预措施: Photodynamic therapy (PDT) (Device)

结局指标

主要结局

Feasibility

时间窗: 2 weeks

Feasibility will be defined as 80% of patients successfully completing the administration protocol as well as 1 week/2-week follow-up.

次要结局

  • Discomfort, burning, itchiness, or redness(2 weeks)
  • Presence of hypergranulation(2 weeks)
  • Pain during light exposure(2 weeks)
  • Treatment Evaluation Inventory-Short Form (TEI-SF)(2 weeks)
  • System Usability Scale (SUS)(2 weeks)
  • Bioburden quantification (16S rRNA sequencing)(2 weeks)
  • Bioburden quantification (Optical Coherence Tomography (OCT)(2 weeks)
  • OCT "virtual biopsy"(2 weeks)
  • Scar thickness(2 weeks)
  • Blood vessel density(2 weeks)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Ida Leah Gitajn

Section Chief, Orthopaedics

Dartmouth-Hitchcock Medical Center

研究点 (1)

Loading locations...

相似试验